They will, no doubt, be spoiled, in the manner of China s Little Jewels or Italy s Mamacinos. Nations have different demographic profiles, as suggested by Figure 1. There may be mitigating factors to take into account. Figure 2 contrasts contemporary sources of mortality in the world heavily weighted of the poor nations and Europe. The progress which Europe has made in the management of disease will continue to be reflected elsewhere, with people in the wealthy nations living longer and wealthy people living longest.
Wealth buys health, in actuarial terms.
However, science makes health cheaper to buy, and offers quite new possibilities. Cloned organs, treatments individually tailored to regenerate mutation-speckled genomes and neural regeneration will be feasible. The biochemistry of neoplasms will be deeply understood. Genome profiling will tell us what weaknesses to watch for, and will prescribe regimes which avoid challenge to this weakness. We may get our medical retaliation in first.